Comparative evaluation of standard criteria and CA-125 in ovarian cancers treated with platinum or paclitaxel.
OBJECTIVE
To assess CA-125 in defining tumor response in patients treated with paclitaxel.


METHODS
We analyzed 150 women treated for epithelial ovarian carcinoma with platinum or paclitaxel. We compared the patients treated with two agents, using a precise definition of CA-125 response, determined by 50% and 75% reductions, like other authors have published.


RESULTS
CA-125 criteria gave response rates very similar to the standard response rates, both for patients treated with platinum (75% vs 63%) and also for those treated with paclitaxel (40% vs 39%). Rates of false-positive prediction of response by CA-125 were also similar for patients treated with these two agents.


CONCLUSIONS
Precise 50% or 75% CA-125 response criteria are as sensitive as standard criteria for assessing activity of therapy for the ovarian cancers treated with platinum or paclitaxel. We propose that they may be useful in defining response in lieu of or in addition to standard response criteria in clinical trials involving epithelial ovarian cancer.
Department of Gynecology and Obstetrics and Neonatology Second University of Naples, Naples, Italy.
G C
GC
Balbi
A
A
Cardone
M
M
Passaro
M
M
Battista
A
A
Monteverde
S
S
Visconti
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D017239:Paclitaxel / Q000627:therapeutic use*; D018579:Patient Selection; D017671:Platinum Compounds / Q000627:therapeutic use*; D012074:Remission Induction
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D017671:Platinum Compounds; D017239:Paclitaxel